May 21, 2014 by Arezu Sarvestani
Zimmer is poised to become the 2nd-largest player in the orthopedics space by absorbing Biomet, and the company expects to need the entire sales force of both companies.
Zimmer (NYSE:ZMH) president & CEO David Dvorak is looking to avoid layoffs as much as possible following the pending mega-merger with long-time rival Biomet.
Both companies run their own independent distributor networks and Dvorak said he aims to keep both, expecting that the combined portfolio of Zimmer and Biomet products will provide “plenty for those sales reps to do.”
